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Millions of people are treated with anthelmintics to control soil-transmitted helminth infections; yet,
drug distribution in the plasma and gastrointestinal tract compartments and the pathway of drug uptake
into gastrointestinal nematodes responsible for the pharmacological effect are unknown. We assessed
the distribution and uptake of albendazole, albendazole sulfoxide, albendazole sulfone in the hookworm
Heligmosomoides polygyrus in vitro and in vivo as well as the distribution and uptake of albendazole,
mebendazole, and oxantel pamoate in the whipworm Trichuris muris in vitro and in vivo. Oral and
intraperitoneal treatments (100 mg/kg) were studied. Drug quantities in helminths and host compart-
ments (stomach, the contents and mucosa of the small and large intestine, and the plasma) were
determined using HPLC-UV/vis and anthelmintic activities were recorded using phenotypic readout. The
inﬂuence of 1-aminobenzotriazole (ABT), an irreversible and unspeciﬁc cytochrome P450 inhibitor, on
albendazole disposition in mice harboring H. polygyrus was evaluated. In vivo, albendazole was found in
quantities up to 10 nmol per ten H. polygyrus and up to 31 nmol per ten T. muris. ABT did not change the
levels of albendazole or its metabolites in the plasma of mice harboring H. polygyrus or in H. polygyrus,
whereas drug levels in the gastrointestinal tract of host mice doubled. Mebendazole and oxantel
pamoate quantities per ten T. muris were as high as 21 nmol and 34 nmol, respectively. Albendazole
revealed a very dynamic distribution and high rate of metabolism, hence, H. polygyrus and T. muris are
exposed to albendazole and both metabolites via multiple pathways. Diffusion through the cuticle seems
to be the crucial pathway of oxantel pamoate uptake into T. muris, and likely also for mebendazole. No
relationship between concentrations measured in helminths and concentrations in plasma, intestinal
content and mucosa of mice, or drug efﬁcacy was noted for any of the drugs studied.
© 2017 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Soil-transmitted helminth infections, including Trichuris tri-
chiura, Ascaris lumbricoides, and the hookworms (Necator ameri-
canus and Ancylostoma ceylanicum) are a major human health
burden in rural, poverty driven settings in the tropics and subtro-
pics (Hotez et al., 2008). The drugs of choice to treat soil-Parasitology and Infection
, P.O. Box, CH-4002 Basel,
r).
Ltd on behalf of Australian Society ftransmitted helminth infections are albendazole and mebenda-
zole, using a single oral dose in the framework of preventive
chemotherapy programs (World Health Organisation, 2006).
Albendazole shows good efﬁcacy against hookworm infections
(cure rates of 72%) when used at a single oral dosage. However, both
albendazole and mebendazole show only low to moderate efﬁcacy
against trichuriasis (cure rates below 36%) (Keiser and Utzinger,
2008).
Oxantel pamoate was recently shown to be a useful addition to
the current drug armamentarium given its high trichuricidal ac-
tivity (Speich et al., 2015; Keiser et al., 2013).
After oral administration, albendazole is absorbed in low
amounts (about 20e30% in mice and rats) in the small intestine,or Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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metabolite) followed by further metabolism to albendazole sulfone
(an inactive metabolite). Therefore, in plasma and urine the parent
compound can only be found in trace amounts. The main enzymes
responsible for these oxidations are the ﬂavin-containing mono-
oxygenase, cytochrome P450 (CYP) 3A4 and to a smaller extent
CYP1A2 (Dayan, 2003; Rawden et al., 2000). In sheep and rats,
albendazole sulfoxide is transported across the small intestinal wall
from the blood stream into the small intestine, likely due to an
active efﬂux (Merino et al., 2003). The bioavailability of mebenda-
zole is also low and it is extensively metabolized in the liver to
inactivemolecules (Dayan, 2003). Reduction of mebendazole by the
carbonyl reductase was suggested to be the main metabolic
pathway (Nishimuta et al., 2013). With regard to oxantel pamoate,
very little information is available. In a recent study in rats, we
could not quantify any oxantel pamoate in the plasma of rats
following oral administration of 100 mg/kg oxantel pamoate per
bodyweight (Cowan et al., 2016).
From a pharmacological point of view, gastrointestinal nema-
todes are interesting target organisms. H. polygyrus is a lumen-
dwelling nematode in the anterior duodenum of the mouse host,
likely feeding on the epithelial cells of the host rather than the
host’s ingesta or blood directly (Bansemir and Sukhdeo, 1994).
T. muris' anterior part is anchored in the epithelial cells of the in-
testinal wall, feeding on the host's mucosa, the largest portion of
their body lays freely in the intestinal tract (Tilney et al., 2005).
Anthelmintics can therefore hypothetically enter the worms via the
epithelial cells, thus from the blood stream via the cytoplasm, or
from the gastrointestinal tract via cuticular penetration. It is
currently not known how anthelmintics reach their target. It has
been suggested that drugs enter intestinal nematodes via the
cuticle (Alvarez et al., 2007). This was for example observed for the
standard anthelmintic ivermectin in lambs infected with Hae-
monchus contortus residing in the abomasum, but feeding on blood.
In more detail, lambs treated with ivermectin intraruminally
showed higher ivermectin levels in H. contortus than lambs treated
subcutaneously that had higher plasma levels (Lloberas et al.,
2012). Also fenbendazole enters Trichuris suis in host pigs via the
transcuticular pathway. On the other hand, fenbendazoles major
metabolites, oxfendazole and fenbendazole sulfone, were sug-
gested to enter via the blood-enterocyte interface. The latter
assumption was made because the concentration of the metabo-
lites found in the worms correlated best with plasma concentra-
tions, but less with their concentrations of the parent compound
observed in the plasma or the gastrointestinal tract (Hansen et al.,
2014).
The goal of this study was to investigate the pathway of drug
uptake into two yet uninvestigated gastrointestinal nematodes. Our
ﬁndings might help to clarify whether the differences in albenda-
zole's efﬁcacy against hookworm and Trichuris correlate with the
extent of drug uptake. We studied the mode of drug entry of
albendazole and its metabolites albendazole sulfoxide and alben-
dazole sulfone into the hookworm Heligmosomoides polygyrus (also
referred to as H. bakeri), and albendazole, mebendazole, and
oxantel pamoate into thewhipworm T. muris in vitro and in vivo. For
that purpose we studied the inﬂuence of drug concentration and
time of drug exposure on drug accumulation in the parasites both
in vitro and in vivo. For in vivo studies, we additionally measured
drug concentrations in compartments that might inﬂuence drug
uptake into the helminths, i.e. plasma, and contents and mucosa of
the gastrointestinal tract. Complementary in vitro and in vivo tests
on H. polygyrus were performed with 1-aminobenzotriazole (ABT),
an unselective and irreversible CYP-inhibitor, to assess the
involvement of CYPs in albendazole's metabolism in host and
parasite.Finally, we assessed drug activities of albendazole sulfoxide as
well as albendazole plus ABT in vitro and in vivo to clarify the role of
the active albendazole metabolite and CYP inhibition.
A better understanding about the pharmacokinetics in the host-
parasite systemwill improve the knowledge of existing treatments
and shed light on characteristics needed for new drugs.
2. Materials and methods
2.1. Animals and parasites
All animal experiments were authorized by the Canton Basel-
Stadt (license number 2070). Four-week-old female NMRI mice
were ordered from Charles Rivers (Sulzfeld, Germany). After a one-
week adjustment period to the animal facilities, the NMRI mice
were infected via oral gavage of 200 or 80 H. polygyrus L3 stage
larvae for in vitro or in vivo experiments, respectively. Four-week-
old female C57BL/10 mice were purchased from Harlan (Black-
thorn, UK). The mice received dexamethasone (Sigma-Aldrich,
Buchs, Switzerland) in the drinking water (1 mg/l) to immuno-
suppress the mice and support worm establishment until oneweek
before treatment. After one week of adjustment, the mice were
infected with 200 T. muris eggs. All mice were kept in animal fa-
cilities at 22 C, 50% humidity, with a 12-h light/dark cycle, and
water and rodent food (KLIBA NAFAG, Switzerland) ad libitum.
2.2. Drugs and solvents
Albendazole, albendazole sulfoxide, mebendazole, 4-
azabenzimidazole, and ABT were purchased from Sigma-Aldrich.
Albendazole sulfone was purchased from Witag (Germany) and
oxantel pamoate from Megaﬁne Pharma (P) Ltd. (India). Methanol
(Sigma-Aldrich) and acetonitrile (Biosolve, Netherlands) were of
HPLC-grade. Ammonium formate and formic acid (both Sigma-
Aldrich) were used to prepare buffer (25 mM ammonium
formate, pH 4.0) for the HPLC measurements.
2.3. In vitro studies
2.3.1. Drug exposure of H. polygyrus for drug entry experiments
Adult H. polygyrus were harvested from infected mice by
dissection, from ten days post-infection onwards. RPMI 1640 cul-
ture medium (Sigma-Aldrich) was supplemented with 500 U/ml
penicillin, 500 mg/ml streptomycin (LuBioScience, Switzerland),
and 2.5 mg/ml amphotericin B (Sigma-Aldrich). The worms were
maintained at 37 C and 5% CO2. Albendazole, albendazole sulf-
oxide and albendazole sulfone were prepared to 10 mM stock so-
lutions in dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and diluted
in culture medium to 5, 10, 25, 50, 75, and 100 mM to a ﬁnal volume
of 2 ml. Ten worms per well were added and the assay was incu-
bated for 24 h. Furthermore, H. polygyrus were exposed to 50 mM
albendazole for 1, 2, 4, 8, 16, and 24 h. The effect of ABT on
H. polygyrus' metabolism of the drugs was assessed by incubating
worms at 50 mM ABT for 16 h and then adding 50 mM albendazole
for an additional incubation period of 8 h. All experiments were
performed in duplicates and repeated once.
2.3.2. Drug activity of albendazole, albendazole sulfoxide and
albendazole sulfone
For the determination of the activity of albendazole, albendazole
sulfoxide and albendazole sulfone, four H. polygyrus per drug were
incubated in 2 ml at 200 mM for 72 h. The drug effect was deter-
mined using a phenotypic readout, evaluating parasite motility,
transparency, and morphology on a scale between three (normal
phenotype) and zero (highly impaired phenotype; dead parasite)
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were compared to control worms that had been incubated in DMSO
of equivalent volume as the drug-containing wells. The experi-
ments were performed in duplicate and repeated once.
2.3.3. Drug exposure of T. muris to albendazole, mebendazole and
oxantel pamoate
Adult T. muris were harvested from infected mice by dissection,
40 days post-infection onwards. The culture medium consisted of
RPMI 1640 medium supplemented with 100 U/ml penicillin,
100 mg/ml streptomycin, and 2.5 mg/ml amphotericin B. The worms
were kept at 37 C and 5% CO2. T. muriswere exposed to 5,10, 25, 50,
75, and 100 mM albendazole, mebendazole and oxantel pamoate
and evaluated 24 h later. In addition, worms incubated in 2 ml of
25 mM oxantel pamoate were evaluated 1, 2, 4, 8, 16, and 24 h post-
incubation. The assays were done in duplicate and repeated on a
different day.
2.3.4. Washing the helminths after drug exposure
To remove drug from the helminth cuticle after in vitro drug
incubations, the worms were brieﬂy dried with a paper towel,
washed brieﬂy (<30 s) in 35 ml 0.9% sodium chloride (NaCl) in
water solution, dried again with a paper towel and placed into a
1.5 ml conical Eppendorf tube. To conﬁrm completeness of the
cleaning process, samples of the NaCl solution after washing the
worms (three samples of each treatment and concentration) were
collected for measurements. In addition, the medium in which the
helminths had been incubated was collected and ﬁltered. The
collected media samples and washing solutions were stored
at 20 C until usage. Worm samples were frozen with liquid ni-
trogen to weaken the cuticle and then stored at 20 C until usage.
2.4. In vivo studies
2.4.1. Treatment of infected mice for drug distribution and activity
studies
Albendazole, albendazole sulfoxide, and ABT were suspended in
7% Tween 80, 3% ethanol, and 90% water (v/v/v). H. polygyrus-
infected mice were treated orally with 100 mg/kg albendazole
(n ¼ 16), 100 mg/kg albendazole with a pre-treatment of 50 mg/kg
ABT (applied 16 h in advance (Boily et al., 2015)) (n ¼ 20), or with
100 mg/kg albendazole sulfoxide (n ¼ 20). The same treatments
were also applied into the peritoneal cavity to groups of four mice.
The control group consisted of four mice that remained untreated.
Mice harboring the T. muris infection were treated by oral
gavage with 100 mg/kg albendazole, 100 mg/kg mebendazole, or
100mg/kg oxantel pamoate to groups of twelvemice per treatment
arm. These treatments were also applied intraperitoneally to
groups of three mice at 100 mg/kg for albendazole, 100 mg/kg
mebendazole, or 50 mg/kg oxantel pamoate. Three mice remained
untreated to serve as control group.
2.4.2. Sampling of the compartments and helminths
H. polygyrus- and T. muris-infected and treated mice were
euthanized 2, 5, or 8 h post-treatment, in groups of four or three,
respectively, at each time point. These time points were chosen due
to an estimated passage time through the gastrointestinal tract in
mice of 6e8 h (Padmanabhan et al., 2013). The groups that had
received a peritoneal application were euthanized 2 h post-
treatment. The blood was collected via heart puncture and the
plasma was obtained using heparinized tubes (Sarstedt,
Switzerland) and centrifugation (10 min at 16’000 g). The stomach,
small intestine and large intestine (cecum till rectum) were cut
open longitudinally and the small intestine was cut into 6 cm long
sections. The intestines of mice that had received drug viaintraperitoneal applicationwere carefully dried with a paper towel,
washed in 300 ml NaCl solution (while clamping both ends of the
gastrointestinal tract and holding above water), and dried again
prior to the sectioning and sampling. Samples of ten H. polygyrus or
T. muris were removed from the small or large intestine, respec-
tively, and washed two times in 35 ml of fresh NaCl solution in 50-
ml tubes. The worms were dried on a paper towel and placed into a
1.5 ml conical Eppendorf tube. The entire content of each gastro-
intestinal unit (stomach, small intestine, and large intestine) was
individually collected. The walls of the small and large intestine
were dabbed with a paper towel to remove remaining debris and
were washed in 50-ml tubes ﬁlled with 35 ml of NaCl solution. The
washed gastrointestinal wall pieces were dried with a paper towel
to remove excess water, then, the mucosa was scraped off using a
scalpel. The samples were stored at 20 C until usage.
2.4.3. Drug activity of albendazole sulfoxide and albendazole after
ABT pre-treatment against H. polygyrus
Six days after the treatment of H. polygyrus-infected mice, mice
(n ¼ 4 per treatment group) were euthanized. The worms were
counted and the count was compared to the worm burden of four
untreated control mice to determine the worm burden reduction
(WBR) (Tritten et al., 2012).
2.5. Determination of drug concentrations in parasites and mice
2.5.1. Processing of helminth samples
In order to weaken the integrity of the cuticle, the worms were
thawed and re-frozen with liquid nitrogen for 2 min. Fifty ml water
and 4-azabenzimidazole in methanol (serving as internal standard
at 75 ng/75 ml in the sample for injection) were added to the
thawed samples and the worms were ground using a plastic pistil
ﬁtting the 1.5 ml conical tubes (HuberLab AG, Switzerland). The
drugs were extracted from the worm suspension by adding 200 ml
of pure acetic acid, centrifugation (10 min at 16’000 g), transferring
the supernatant into a new tube and evaporating the solvent at
65 C using a SpeedVac SPD 111V concentrator (Thermo Fisher
Scientiﬁc, Germany). The extraction step was repeated once. The
dried drug samples were reconstituted with 75 ml of 10% (v/v)
acetonitrile in ammonium formate aqueous buffer.
Three samples of both helminth species, all untreated, were
processed and checked for background peaks at the retention times
of all ﬁve analytes, plus the internal standard.
2.5.2. HPLC apparatus and parameters
An Agilent Series 1100 (Agilent Technologies, Inc.) was used for
HPLC analyses as described elsewhere (Cowan et al., 2016). The
separations were conducted at a ﬂow rate of 1 ml/min, using two
pumps, a microvacuum degasser, an autosampler (10 C), and a
column heater (25 C). A reversed phase Kinetex® XB-C18 column
(4.5  150 mm, 2.6 mm; Phenomenex, USA) was used for all sepa-
rations and a UVevis detector measured the absorption at a
wavelength of 300 nm. The injection volume was 50 ml for all
samples.
2.5.3. Quantiﬁcation of drugs in helminth samples, incubation
media, and NaCl solution used for washing
The calibration curves for albendazole (2.5, 1.25, 0.63, 0.31, 0.16,
and 0.01 mg/ml), albendazole sulfoxide (2.5, 1.25, 0.63, 0.31, 0.16,
and 0.01 mg/ml), and albendazole sulfone (5.0, 2.5, 1.25, 0.63, 0.31,
and 0.16 mg/ml) were prepared in 10% (v/v) acetonitrile in aqueous
ammonium formate buffer. The calibration curves for mebendazole
(2.5, 1.25, 0.63, 0.31, 0.16, 0.08 mg/ml) and oxantel pamoate (2.5,
1.25, 0.63, 0.31, 0.16, 0.08 mg/ml) were prepared separately, also
using 10% acetonitrile in ammonium formate buffer. The internal
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the calibration curves to a concentration of 1 mg/ml, the solutions
were measured using the HPLC parameters described earlier
(Cowan et al., 2016).
The method of quantiﬁcationwas validated for sensitivity at the
retention time of the analytes and the internal standard, the line-
arity of the analytes' calibration curves, and the accuracy and pre-
cision (inter- and intraday). These parameters were determined
using quality control samples of high, intermediate, and low con-
centrations of the respective calibration curve, and at the lower
limit of quantiﬁcation (LLOQ). All parameters were calculated from
three repeats per sample, and at three different days for interday
validation.
The collected culture media of the drug incubations were
ﬁltered through a ﬁlter of 0.2 mm mesh width before injection into
the HPLC. The NaCl wash solutions, that had been used to wash the
worms of the in vitro drug entry experiments, were injected
directly.
2.5.4. Quantiﬁcation of albendazole, albendazole sulfoxide and
albendazole sulfone in plasma and other compartments
Albendazole analysis. A stock solution of 10 mg/ml albendazole
in DMSOwas diluted to 192 mg/ml albendazole in acetonitrile. Then,
a serial dilution in 50% (v/v) acetonitrile in aqueous ammonium
formate buffer was prepared (192, 96, 48, 24, 12, and 6 mg/ml
albendazole) and used to spike blank plasma (Sprague Dawely rat
plasma; DUNN Labortechnik, Germany), resulting in 100 ml spiked
plasma samples (9.6, 4.8, 2.4, 1.2, 0.6, and 0.3 mg/ml albendazole)
containing less than 3% (v/v) organic solvent..
The spiked plasma samples were precipitated using 300 ml
methanol containing internal standard (1.5 mg/ml mebendazole).
The suspension was mixed for 30 s, centrifuged at 16’000 g for
10 min and the supernatant was transferred to a new tube and
dried at 45 C using a SpeedVac concentrator. Then, the pellet was
resuspended with 75 ml of 50% (v/v) acetonitrile in aqueous
ammonium formate buffer. For the chromatography of albendazole,
an acetonitrile gradient between 50% and 90% acetonitrile in
ammonium formate buffer was used during 5 min, detecting at a
wavelength of 300 nm. The method was validated using a high
(7.1 mg/ml), intermediate (1.8 mg/ml), and low concentration
(0.45 mg/ml) within the calibration curve, and the LLOQ (0.3 mg/ml).
Parameters tested were the linearity, sensitivity, selectivity, the
accuracy and precision (intra- and interday), the recovery and
matrix effect. Six replicates of each quality control were used for the
validation.
Albendazole sulfoxide and sulfone analysis. Plasma samples
of 100 ml obtained from the mice experiments at selected time
points were precipitated using 300 ml methanol containing 10 mg/
ml 4-azabenzimidazole, mixed for 10 min, the supernatant was
moved to a new tube, dried in the SpeedVac concentrator, and the
pellets resulting were resuspended in 75 ml of 10% (v/v) aqueous
ammonium formate (Cowan et al., 2016).
Samples of the gastrointestinal tract (stomach, small intestinal
and large intestinal contents, and the small intestinal and large
intestinal mucosa) were diluted with blank Sprague Dawely plasma
to provide a similar biological matrix for extraction and similar
drug quantities as the validated method for plasma samples. The
dilution procedure was as follows: The thawed gastrointestinal
samples were homogenized using a spatula, samples of 100 mg
were taken and prepared to 100 mg gastrointestinal tract sample
per 1 ml plasma. The samples were vortex-mixed, ultrasonicated
for 30 min at 37 C and centrifuged at 16’000 g for 10 min. The
supernatant of these samples was diluted 2-fold (stomach contents,
small and large intestinal mucosas), or 4-fold (small and large in-
testinal contents) with plasma. Hundred ml of the diluted sampleswere processed in the same manner as described for the respective
methods for plasma samples, starting at the precipitation using
300 ml methanol containing the respective internal standard.
This method of diluting the gastrointestinal tract samples in
plasma was assessed for intraday accuracy and precision in the
same manner as the validations of the respective methods
described above, using quadruplicate determination.
Samples of the gastrointestinal tract after treatment with
albendazole or albendazole sulfoxide were analyzed with both
methods. Plasma samples were only analyzed for albendazole
sulfoxide and sulfone, since albendazole is quickly metabolized to
the two metabolites (Dayan, 2003).
2.5.5. Stability of albendazole and albendazole sulfoxide exposed to
gastrointestinal contents
The stability of albendazole and albendazole sulfoxide when
exposed to the content of the stomach, as well as the small and
large intestine was tested. Four untreated NMRI mice were eutha-
nized, the gastrointestinal contents were collected, homogenized,
and 100 mg of each content sample was spiked with 5 mg alben-
dazole or albendazole sulfoxide and incubated at 37 C in a closed
tube. After 24 h, plasma ad 1 ml was added and the samples were
further processed according to the method described above.
2.5.6. Veriﬁcation of albendazole, albendazole sulfoxide and
albendazole sulfone using mass spectrometry
The identities of albendazole, albendazole sulfoxide, and
albendazole sulfone were veriﬁed with mass spectrometry. Worm
samples from in vitro drug assays after incubation at concentrations
of 25 or 50 mM, as well as worms collected from in vivo experiments
were assayed. In addition, a sample of each compartment (stomach,
small intestinal content and mucosa, and large intestinal content
and mucosa) of both parasite models was tested. For the separation
using HPLC (Shimadzu, Kyoto, Japan) the chromatographic pa-
rameters were applied as describe above. For the MS measure-
ments the compounds were ionized in positive mode and detected
by multiple reaction monitoring on an API 3200 (AB Sciex; Fra-
mingham, USA) equipped with a turbo ion spray source.
2.6. Data analysis
Microsoft Excel 2010 was used for all calculations. The accuracy
of the analytical methods was determined from the average value
of replicates, and the precision was expressed as the coefﬁcient of
variation (CV), which was calculated as the ratio of the normalized
peak area's standard deviation to the mean value. Multiple mea-
surements of test samples were averaged (arithmetic mean) and
the standard deviation (SD) was calculated. The presence of cor-
relation was deﬁned as a correlation coefﬁcient (R2) of the linear
trend line if R2  0.75. The LLOQs for the different sample types
(helminths, gastrointestinal tract, and plasma or culture medium)
are listed in Table S1 of the supplementary ﬁle.
3. Results
3.1. Quality of in vitro and in vivo experiments and the analytical
measurements
Analytes in solvent. The calibration curves of all ﬁve analytes in
solvent were linear (all R2 ¼ 0.999) and the measurements of the
quality controls were accurate and precise, revealing coefﬁcient of
variation between measurements of ±14% for the higher, middle
and lower quality controls, or ±18% for LLOQ (supplementary ﬁle
Table S2).
Analyte extraction from helminth suspension.
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and T. muris showed that the absorption signals (peak area and
height) at the retention times of interest were at least ﬁve times
smaller than the signals (peak area and height) of the LLOQ of the
respective analyte. Results of background signals of T. muris versus
analyte signals are presented in the supplementary ﬁle Table S3.
Helminth washing solution. NaCl solutions which had been
used for washing the worms after drug incubations contained
acceptable amounts of residual drug: out of 48 washing solutions
tested (including both helminths and the respective analytes that
had been used for in vitro drug exposure between 5 and 100 mM) 46
(96%) revealed drug levels which were below the LLOQ.
Quantiﬁcation of albendazole in plasma. The calibration curve
of the quantiﬁcation of albendazole in plasma was linear
(R2 ¼ 0.999). The absorption at the retention time showed a 4.3-
fold lower peak height than at LLOQ. All quality controls were
measured accurately (±6%) and precisely (8%) (supplementary ﬁle
Table S4). The recovery of albendazole from spiked plasma samples
was 93% (±1) and the matrix effect was 91% (±1) (supplementary
ﬁle Table S5).
Stability in gastrointestinal tract content samples. No
biotransformationwas observed using HPLC when albendazole and
albendazole sulfoxide were incubated with blank samples of the
gastrointestinal contents for 24 h.
Accuracy and precision in compartment samples. Albenda-
zole sulfoxide, albendazole sulfone, and mebendazole were accu-
rately and precisely quantiﬁable in gastrointestinal compartment
samples (stomach content, small intestinal content and mucosa,
and large intestinal content and mucosa) at the higher and middle
quality control concentrations. The amount of albendazole and
oxantel pamoate in the two lower concentration of quality controls
was above the expected values, up to 139% (small intestinal mu-
cosa) and 128% (small intestinal content), respectively. The con-
centrations in the stomach at the lower end of the calibration
curves were overestimated for all analytes (between 123% and 175%
of the expected value). The accuracy and precision of the quanti-
ﬁcation in the processed and spiked gastrointestinal tract samples
are shown in Table S6 of the supplementary ﬁle.
MS veriﬁcation of metabolites. The presence of metabolites
albendazole, albendazole sulfoxide and albendazole sulfone quan-
tiﬁed with the HPLC methods was conﬁrmed with LC-MS/MS for all
different of samples used in this study.
3.2. Drug uptake and elimination by H. polygyrus and T. muris
in vitro
Uptake and elimination of albendazole by H. polygyrus. After
H. polygyrus were incubated with albendazole at concentrations
ranging from 5 to 100 mM for 24 h, albendazole (5e55 nmol/10
worms), albendazole sulfoxide (14e110 nmol/10 worms), and
albendazole sulfone (2e22 nmol/10 worms) were detected in
worms (Table 1). There was no linear correlation between assay
concentration and the concentrations found in the parasite. The
culture medium after incubation contained on average 0.5 mM
(0.3e0.6 mM) albendazole sulfoxide. Albendazole sulfone could not
be quantiﬁed in the medium.
Between 1 and 8 h of incubation of H. polygyrus with albenda-
zole at 50 mM, a linear time-dependent accumulation of both
albendazole (R2 ¼ 0.95) and albendazole sulfoxide (R2 ¼ 0.92) was
measured (supplementary ﬁle Fig. S1). Longer incubation than 8 h
did not increase drug concentration in the worms, but plateaued at
29 nmol/10 worms for both compounds. The albendazole sulfoxide
concentration in the culture medium, on the other hand, was
measured at similar concentrations between 1 and 24 h of incu-
bation with an overall average of 0.7 mM (0.6e1 mM).When H. polygyruswas exposed to albendazole following a pre-
incubation with ABT, no differences in the accumulation of alben-
dazole or its metabolites were found in the worms and in the
culture medium.
Uptake and elimination of albendazole sulfoxide by
H. polygyrus. After incubation of H. polygyrus with albendazole
sulfoxide (5e100 mM) for 24 h, between 12 nmol/10 worms and 111
nmol/10 worms were detected in a concentration dependent
manner (R2 ¼ 0.86) (Table 1). Albendazole sulfone was also
detected, however, at amounts no higher than 16 nmol/10 worms.
Neither albendazole nor albendazole sulfone could be quantiﬁed in
the culture medium.
Uptake and elimination of albendazole sulfone by
H. polygyrus. Incubation of H. polygyrus with albendazole sulfone
yielded similar quantities regardless of concentration tested
(5e100 mM): albendazole sulfone was present at a mean of 33
nmol/10 worms (23e51 nmol/10 worms) and albendazole sulf-
oxide at 15 nmol/10 worms (9e19 nmol/10 worms) (Table 1).
Albendazole sulfoxide was found in the medium on average at
25 mM (19e39 mM).
Uptake and elimination of albendazole by T. muris. After in-
cubation of T. muris with albendazole between 5 and 100 mM for
24 h, albendazole and its metabolites were measured in a
concentration-dependent manner after exposure between 5 and
75 mM in culture medium (Table 1). Albendazole was detected at
the highest quantities ranging from 94 to 598 nmol/10 worms
(R2¼ 0.94), followed by albendazole sulfoxidewhich wasmeasured
at concentrations ranging from 45 to 211 nmol/10 worms
(R2 ¼ 0.78), and albendazole sulfone at 15e149 nmol/10 worms
(R2¼ 0.95). The albendazole sulfoxide concentrations in the culture
medium (ranging from 1 to 5.2 mM) increased with increasing
albendazole concentrations of incubation. Albendazole sulfone was
not detected in the culture medium.
Uptake and elimination of albendazole sulfoxide by T. muris.
Exposure of T. muris to albendazole sulfoxide resulted in concen-
trations of 61 (after exposure to 5 mM) to 833 nmol/10 worms (after
exposure to 100 mM), which increased linearly at a concentration
range from 5 to 75 mM drug in the culture medium (R2 ¼ 0.96)
(Table 1). Albendazole sulfone was detected at low and similar
amounts in all samples at an average of 7 nmol/10 worms
(3e10 nmol/10 worms).
Uptake and elimination of albendazole sulfone by T. muris.
Albendazole sulfone was absorbed into T. muris in a concentration-
dependent manner (122e1348 nmol/10 worms (R2 ¼ 0.97))
following incubation of 5e100 mM. Albendazole and albendazole
sulfoxide were neither detected in the parasite nor the culture
medium (Table 1).
Uptake of mebendazole by T. muris. The entry of mebendazole
into T. muris slightly increased with escalating drug concentration.
The mebendazole amounts measured ranged between 482 and
910 nmol/10 worms following incubation of 5e100 mM for 24 h
(Table 1).
Uptake of oxantel pamoate by T. muris. Oxantel pamoate was
detected at levels of 13e197 nmol/10 worms in a concentration-
dependent manner (R2 ¼ 0.94) (Table 1). The uptake of oxantel
pamoate ceased 8 h after exposure to the drug at 25 mM (supple-
mentary ﬁle Fig. S2).
3.3. Drug distribution and biotransformation in infected animals
and parasites
3.3.1. Drug distribution in the gastrointestinal tract and plasma of
NMRI mice harboring H. polygyrus
Albendazole treatment. After oral treatment with albendazole,
albendazole and albendazole sulfoxide were detected in all
Table 1
In vitro drug uptake and elimination after 24 h exposure to albendazole (ABZ), albendazole sulfoxide (ABZSO), and albendazole sulfone (ABZSO2) by H. polygyrus and T. muris, as well as uptake of mebendazole (MBZ) and oxantel
pamoate (OxP) by T. muris.
H. polygyrus T. muris






ABZ ± SD ABZSO ± SD ABZSO2 ± SD ABZ ± SD ABZSO ± SD ABZSO2 ± SD ABZ ± SD ABZSO ± SD ABZSO2 ± SD ABZ ± SD ABZSO ± SD ABZSO2 ± SD Conc. of
incub.
[mM]




ABZ 5 13 ± 6 14 ± 19 3 ± 3 ND 0.4 ± 0.2 NP 94 ± 44 45 ± 64 15 ± 18 ND 1.0 ± 0.5 MBZ 5 482 ± 388 OxP 5 13 ± 9
10 16 ± 5 51 ± 9 5 ± 2 ND 0.4 ± 0.3 NP 176 ± 83 38 ± 35 67 ± 34 ND 2.0 ± 0.5 10 626 ± 463 10 27 ± 9
25 5 ± 8 44 ± 14 22 ± 31 ND 0.5 ± 0.2 NP 263 ± 173 106 ± 178 90 ± 43 ND 2.6 ± 0.9 25 672 ± 251 25 65 ± 5
50 28 ± 4 30 ± 10 2 ± 3 ND 0.6 ± 0.3 NP 551 ± 528 259 ± 285 103 ± 64 ND 3.5 ± 1.1 50 826 ± 390 50 155 ± 41
75 55 ± 49 99 ± 7 13 ± 25 ND 0.6 ± 0.3 NP 598 ± 336 211 ± 224 149 ± 64 ND 5.2 ± 1.0 75 910 ± 362 75 169 ± 24
100 10 ± 21 110 ± 70 10 ± 12 ND 0.3 ± 0.4 NP 641 ± 467 221 ± 224 141 ± 50 ND 3.9 ± 0.5 100 861 ± 503 100 197 ± 46
ABZSO 5 NP 27 ± 12 16 ± 32 NP ND NP NP 61 ± 18 6 ± 5 NP ND
10 NP 12 ± 8 0.5 ± 0.0 NP ND NP NP 131 ± 79 8 ± 6 NP ND
25 NP 31 ± 6 5 ± 3 NP ND NP NP 282 ± 114 3 ± 3 NP ND
50 NP 56 ± 16 12 ± 10 NP ND NP NP 563 ± 141 8 ± 4 NP ND
75 NP 77 ± 15 4 ± 4 NP ND NP NP 787 ± 252 7 ± 5 NP ND
100 NP 111 ± 50 15 ± 25 NP ND NP NP 833 ± 229 10 ± 4 NP ND
ABZSO2 5 NP 19 ± 10 33 ± 10 NP 0.2 ± 0.1 ND NP NP 122 ± 45 NP NP ND
10 NP 19 ± 3 51 ± 23 NP 0.2 ± 0.1 ND NP NP 185 ± 55 NP NP ND
25 NP 13 ± 11 23 ± 8 NP 0.4 ± 0.0 ND NP NP 421 ± 171 NP NP ND
50 NP 9 ± 5 30 ± 20 NP 0.3 ± 0.0 ND NP NP 780 ± 258 NP NP ND
75 NP 16 ± 11 31 ± 8 NP 0.3 ± 0.0 ND NP NP 1127 ± 451 NP NP ND
100 NP 16 ± 8 33 ± 21 NP 0.2 ± 0.0 ND NP NP 1348 ± 447 NP NP ND
NP: No peak detected; ND: Not done; values are averages of n ¼ 4 ± standard deviation (SD).






















Fig. 1. In vivo distribution of albendazole treatments in host and H. polygyrus. Columns of host samples are averages of n ¼ 4 mice and columns of parasite samples are averages of
n ¼ 12 measurements (3 samples per mouse). Error bars indicate the standard deviation. ABZ: Albendazole (black columns); ABZSO: albendazole sulfoxide (gray columns);
albendazole sulfone (white columns); po: per oral; ip: intraperitoneal; GI: gastrointestinal.
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pling times post-treatment (2, 5, and 8 h). In more detail, in the
stomach the concentration of albendazole was on average
234 mmol/g (156e373 mmol/g), 170 mmol/g (110e260 mmol/g) for
albendazole sulfoxide, and 8 mmol/g (4e16 mmol/g) for albendazole
sulfone. In the small intestine, where H. polygyrus resides, alben-
dazole concentrations were on average 111 mmol/g (58e169 mmol/
g), albendazole sulfoxide concentrations were on average 51 mmol/
g (24e79 mmol/g), and albendazole sulfone was not measured. In
the large intestine, the concentrations of albendazole and alben-
dazole sulfoxide decreased over time from 462 mmol/g
(349e700 mmol/g) to 99 mmol/g (0e186 mmol/g) and from 71 mmol/
g (53e110 mmol/g) to 56 mmol/g (16e112 mmol/g), respectively,
whereas the sulfone metabolite was only found in low amounts
(below 11 mmol/g). The concentrations in the mucosa were only
quantiﬁable after 8 h for albendazole at 13 mmol/g (0e40 mmol/g)
and albendazole sulfoxide at 27 mmol/g (6e47 mmol/g). Plasma
concentrations were on average 13.5 mM (5.4e21.2 mM) for alben-
dazole sulfoxide and 2.2 mM (0.7e3.3 mM) for albendazole sulfone
(Fig. 1B). A correlation was observed between the concentration of
albendazole sulfoxide in plasma and the content of the small in-
testine (R2 ¼ 0.77). No relation between other compartments and
drugs were found.
Two hours after intraperitoneal treatment of 100 mg/kg alben-
dazole to NMRI mice elevated concentrations of albendazole (20-
fold), albendazole sulfoxide (62-fold), and albendazole sulfone
(493-fold) were observed in all gastrointestinal contents (Fig. 1C)
compared to oral treatment. The stomach contained albendazole at
2217 mmol/g (0e5259 mmol/g), albendazole sulfoxide at 6486 mmol/
g (2725e15225 mmol/g) and sulfone at 3264 mmol/g (0e7832 mmol/
g). Albendazole was detected in the small intestinal content at
486 mmol/g (0e1945 mmol/g), albendazole sulfoxide at 6391 mmol/g
(905e10367 mmol/g), and albendazole sulfone at 4396 mmol/g
(3149e6606 mmol/g). In the large intestinal content, albendazole
was detected at 10620 mmol/g (3398e28518 mmol/g), albendazole
sulfoxide at 1356 mmol/g (634e3064 mmol/g), and albendazole
sulfone at 3988 mmol/g (0e5730 mmol/g). Albendazole was not
found in the small intestinal mucosa. Albendazole sulfoxide and
sulfone were quantiﬁed in the mucosal tissues of the small intes-
tine in concentrations of 1439 mmol/g (433e2148 mmol/g) and
683 mmol/g (627e781 mmol/g), respectively. In the large intestinal
mucosa, albendazole concentrations were 416 mmol/g
(0e856 mmol/g), albendazole sulfoxide 1060 mmol/g
(434e1627 mmol/g), and albendazole sulfone 805 mmol/g
(0e1078 mmol/g). In the plasma, albendazole sulfoxide was present
at 3222 mM (770e4657 mM) and albendazole sulfone at 527 mM
(212e705 mM) (Fig. 1C).
Albendazole with ABT pre-treatment. Oral pre-treatment with
ABT followed by albendazole resulted at all time points in higher
albendazole levels in the stomach (average of 2.7-fold magnitude)
thanwithout ABT (Fig.1D). In the small intestinal content therewas
a tendency for a higher albendazole sulfoxide concentration (2.1-
fold), and in the large intestinal content, both albendazole and its
sulfoxide metabolite were elevated on average 1.9-fold and 2.4-fold
between 2 and 8 h post-treatment, respectively compared to
albendazole monotherapy. In the mucosa of the small intestine,
levels of albendazole were on average 19 mmol/g (0e176 mmol/g)
across all time points and of albendazole sulfoxide on average
14 mmol/g (6e26 mmol/g), whereas no albendazole sulfone was
present. The albendazole levels in the mucosa of the large intestine
were on average 3.8-fold elevated over time compared to alben-
dazole single treatment, and albendazole sulfoxide was 2.8-fold
elevated, whereas albendazole sulfone was also not present after
this treatment. In the plasma, increased exposure of albendazole
sulfoxide (2-fold on average between 2 and 8 h post treatment) wasobserved (Fig. 1E). Levels of albendazole sulfone in the plasmawere
not inﬂuenced by the ABT pre-treatment, but showed the same
concentrations as the albendazole treatment. No correlation be-
tween the concentrations of any drugs in any of the compartments
could be identiﬁed.
Elevated concentrations of albendazole and its metabolites (28-
fold, 44-fold and 237-fold increase of albendazole, albendazole
sulfoxide, and albendazole sulfone, respectively) were observed in
the gastrointestinal tract after parenteral application of albenda-
zole following ABT pre-treatment compared to the oral application
of the two drugs (Fig. 1F). Albendazole and its metabolites were
slightly elevated (within 2-fold difference) in themucosa compared
to albendazole single treatment applied intraperitoneally.
Albendazole sulfoxide treatment. After the oral application of
albendazole sulfoxide to H. polygyrus-infected mice, albendazole
and both metabolites were found in the contents of the gastroin-
testinal tract (Fig. 1G). In all compartments and at all time points
albendazole sulfoxide was the predominant entity detected on
average of 8-fold higher compared to albendazole and albendazole
sulfone. Albendazolewas found in the stomach on average 76 mmol/
g (7e133 mmol/g), in the small intestine 12 mmol/g (4e17 mmol/g)
and in the large intestine at 211 mmol/g (156e344 mmol/g) across all
time points. In the mucosa of the small intestine, albendazole,
albendazole sulfoxide and sulfone were detected at highest con-
centrations 5 h after treatment, with 15 mmol/g (0e53 mmol/g),
137 mmol/g (82e289 mmol/g) and 5.7 mmol/g (1e10 mmol/g),
respectively. At the other time points tested, albendazole concen-
trations were below 1 mmol/g, and albendazole sulfoxide and
albendazole sulfone concentrations were below 27 mmol/g, 3 mmol/
g, respectively. The mucosal tissue of the large intestine contained
between 9 and 13 mmol/g albendazole, 16 and 30 mmol/g albenda-
zole sulfoxide, and below 2 mmol/g albendazole sulfoxide between
2 and 8 h post-treatment. Albendazole sulfoxide found in the
plasma was increased compared to the albendazole treatment,
especially 5 h post-treatment (5.2-fold elevated levels of albenda-
zole sulfoxide) (Fig. 1H). The concentration of albendazole sulfoxide
in the plasma correlated with the concentration in the contents of
the small intestine (R2 ¼ 0.76) and the large intestine (R2 ¼ 0.78).
When albendazole sulfoxide was given intraperitoneally and
samples were collected 2 h post-treatment no albendazole was
detected in the stomach, but albendazole sulfoxide at 58655 mmol/g
and albendazole sulfone at 10199 mmol/g. In the contents of the
small intestine no albendazole was found, but albendazole and
albendazole sulfone were present at 23488 mmol/g at and
10341 mmol/g, respectively. The concentrations in the large intes-
tinal contents were 23889 mmol/g for albendazole, 3319 mmol/g for
albendazole sulfoxide, and 5542 mmol/g for albendazole sulfone.
Overall, the gastrointestinal tract contained on average more
albendazole (60-fold), albendazole sulfoxide (86-fold), and alben-
dazole sulfone (553-fold) levels compared to the average value of
samples of gastrointestinal contents collected after oral treatment
(Fig. 1I). In the small intestinal mucosa no albendazole was detec-
ted, but albendazole sulfoxide were present at 6302 mmol/g
(3417e7836 mmol/g) and albendazole sulfone at 2307 mmol/g
(2050e2610 mmol/g). In the mucosa of the large intestine alben-
dazole was measured at 1446 mmol/g (909e2698 mmol/g), as well
as albendazole sulfoxide at 2605 mmol/g (1375e4184 mmol/g) and
albendazole sulfone at 2416 mmol/g (2065e2675 mmol/g). In the
plasma, albendazole sulfoxide was present at 11726 mM
(6667e14477 mM) and albendazole sulfone at 2646 mM
(1622e3255 mM).
Uptake of albendazole and its metabolites by H. polygyrus
in vivo. In H. polygyrus recovered from mice orally treated with
albendazole and albendazole plus ABT, the albendazole amounts
were on average 6.2 nmol/10 worms (3e10 nmol/10 worms),
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amounts with 9.1 nmol/10 worms (5e16 nmol/10 worms) (Fig. 1J).
Albendazole sulfone, on the other hand, was only detected in
worms of mice that had not been pretreated with ABT (on average
7.3 nmol/10 worms (1e15 nmol/10 worms)). Oral application of
albendazole sulfoxide resulted in accumulation of the two alben-
dazole metabolites in the worms. No albendazole was detected.
Albendazole sulfoxide was found at amounts of 11.4 nmol/10
worms (9.8e14 nmol/10 worms) and albendazole sulfone at 23.1
nmol/10 worms (11e34 nmol/10 worms). After intraperitoneal
application of the three treatments, albendazole sulfoxide was
found in similar amounts as the oral applications. However,
albendazole sulfone concentrations were increased to an average of
86.4 nmol/10 worms (67e109 nmol/10 worms). Albendazole was
only found in one of all H. polygyrus samples (n ¼ 29) recovered of
the intraperitoneal treatment. No relationship between the drug
concentrations in H. polygyrus and the corresponding concentra-
tions in the plasma, large intestinal content or its mucosa could be
observed.
3.3.2. Drug distribution in C57BL/10 mice and T. muris
Albendazole treatment. After oral albendazole treatment,
albendazole, albendazole sulfoxide and albendazole sulfone were
detected in all contents of the gastrointestinal tract, at decreasing
concentrations over time and descending order of amount
throughout the intestinal tract (Fig. 2A). The highest concentrations
between 2 and 8 h post-application were found in the stomach of
the animals with average concentrations over time of 114 mmol/g
(39e174 mmol/g) for albendazole, 234 mmol/g (145e431 mmol/g) for
albendazole sulfoxide, and 34 mmol/g (7e75 mmol/g) for albenda-
zole sulfone. Concentrations in the small intestine dropped from
394 mmol/g (235e622 mmol/g) of albendazole (2 h post-
application) to around 5 mmol/g (5 and 8 h post-application),
albendazole sulfoxide from 146 mmol/g (138e157 mmol/g) 2 h
post-application to 12 mmol/g (3e20 mmol/g) 8 h post-application,
and albendazole sulfone from 44 mmol (0.4e85 mmol/g) 2 h post-
application to 13 mmol/g (3e22 mmol/g) 8 h post-application. The
large intestinal tract, inwhich T. muris resides, contained 208 mmol/
g (97e396 mmol/g), 57 mmol/g (30e97 mmol/g), or 16 mmol/g
(11e19 mmol/g) albendazole at 2, 5, or 8 h post-treatment, respec-
tively. The levels of albendazole sulfoxidewere lowerwith 31 mmol/
g (17e46 mmol/g), 11 mmol/g (1e17 mmol/g), and 5 mmol/g
(4e6 mmol/g) at the given time points. In the mucosa of the small
intestine albendazole, albendazole sulfoxide and sulfone were
detected 2 h post-treatment at 5 mmol/g (0e12 mmol/g), 25 mmol/g
(20e27 mmol/g) and 11 mmol/g (5e16 mmol/g), respectively. Five
and eight hours after application, the albendazole, albendazole
sulfoxide and sulfone levels were below 4 mmol/g. Also in the
mucosa of the large intestine, albendazole was found highest 2 h
after treatment at 13 mmol/g (3e19 mmol/g), albendazole sulfone at
22 mmol/g (15e26 mmol/g), and albendazole at 5 mmol/g
(2e10 mmol/g). After 5 and 8 h, all concentrations were below
6 mmol/g. Plasma levels of albendazole sulfoxide were highest 2 h
post-treatment with 31 mM (24e41 mM) and decreased to 10 mM
(7e14 mM) and 6 mM (4e5 mM) at 5 or 8 h post-treatment (Fig. 2B).
Albendazole sulfone was measured between 5.5 mM (4e8 mM) 2 h
post-treatment to 0.5 mM (0.1e1.2 mM) 8 h post-treatment.
The distribution of albendazole and its metabolites 2 h after the
intraperitoneal application showed similarities to oral treatment of
albendazole 5 h post-treatment. All three drugs were present in all
parts of the intestinal tract. In the stomach, concentrations of
albendazole was 139 mmol/g (77e233 mmol/g), albendazole sulf-
oxide 145 mmol/g (121e167 mmol/g), and albendazole sulfone
15 mmol/g (13e17 mmol/g). Concentrations of albendazole and
albendazole sulfoxide on average 46 mmol/g (32e62 mmol/g) in thesmall and large intestines (Fig. 2C). Albendazole sulfone was
detected at 15 mmol/g in the stomach, 24 mmol/g in the small in-
testine and 6 mmol/g in the large intestine. In the mucosa of the
small intestine, only albendazole sulfoxide was detected at
14 mmol/g (10e21 mmol/g). In the mucosa of the large intestine,
albendazole was detected at 8 mmol/g (0e13 mmol/g) and alben-
dazole sulfoxide at 14 mmol/g (12e15 mmol/g). Plasma values were
in the same range as after oral application with 20.0 mM
(13e24 mM) for albendazole sulfoxide and 2.9 mM (1.7e3.6 mM) for
albendazole sulfone (Fig. 2B).
Worms recovered from the treatedmice revealed albendazole as
well as its metabolites (Fig. 2D). After oral treatment, albendazole
sulfoxide was found in highest amounts (52e91 nmol/10 worms),
which was on average 3.2-fold higher than albendazole and 11-fold
higher than albendazole sulfone. Intraperitoneal treatment resul-
ted in albendazole sulfoxide concentration of 204 nmol/10 worms,
which was 20-fold higher than albendazole and 5.3-fold higher
than albendazole sulfone. There was no correlation between the
drug concentrations measured in T. muris, compared to the plasma
or the large intestinal content.
Mebendazole treatment. As shown in Fig. 2E, 2 h after oral
treatment with mebendazole, most of the drug was found in the
stomach with 215 mmol/g (145e320 mmol/g) and small intestine
with 222 mmol/g (110e402 mmol/g), but less in the large intestine
with 18 mmol/g (9e25 mmol/g). The concentration in the large in-
testine was higher 5 h post-treatment with 100 mmol/g
(64e171 mmol/g), but again lower 8 h post-treatment with 40 mmol/
g (26e55 mmol/g). In the mucosa of the small intestine, 8 mmol/g
(5e22 mmol/g) of mebendazole was present after 2 h post-
treatment, 6 mmol/g (0.2e14 mmol/g) 5 h post-treatment, and
4 mmol/g (2e6 mmol/g). In themucosa of the large intestine, 3 mmol/
g was found in all mice after 2 h post-treatment, 5 mmol/g
(1e11 mmol/g) 5 h post-treatment, and 2 mmol/g (1e3 mmol/g) 8 h
post-treatment. Plasma concentrations were low at 0.7e1.8 mM
(Fig. 2F).
After intraperitoneal treatment with mebendazole, a similar
picture of mebendazole levels was observed in the gastrointestinal
tract as after oral dose 8 h post-treatment (Fig. 2G). In themucosa of
the small and the large intestine, 4 mmol/g (1e6 mmol/g) and
1 mmol/g (0e2 mmol/g) was present, respectively. Plasma levels of
mebendazole, however, resulted in a slightly higher plasma level
compared to the oral treatment with 3.6 mM (2.4e4.7 mM) (Fig. 2F).
After oral treatment with mebendazole, its concentration in
T. muris was close to LLOQ, remaining unchanged over time
(20 nmol/10 worms) (Fig. 2H). Intraperitoneal application of
mebendazole led to less accumulation (5 nmol/10 worms). No
correlation between mebendazole concentration in the worms
compared to drug found in the plasma or content of the large in-
testine was observed.
Oxantel pamoate treatment. After oral treatment with oxantel
pamoate, large amounts of oxantel pamoate were found in the
stomach (5278 mmol/g [467e14373 mmol/g] 2 h post-treatment),
which decreased to 302 mmol/g (75e601 mmol/g) and 364 mmol/g
(52e792 mmol/g), at 5 and 8 h post-treatment, respectively. In the
small intestine 1951 mmol/g (106e3394 mmol/g) were detected 2 h
post-treatment, which decreased to 54 mmol/g (17e104 mmol/g)
and 61 mmol/g (40e82 mmol/g) 5 and 8 h post-treatment, respec-
tively. The oxantel pamoate concentrations in the large intestine
altered over the sampling time points of 2, 5 and 8 h post-treatment
from 6 mmol/g (4e6 mmol/g) to 359 mmol/g (48e587 mmol/g) and
110 mmol/g (0e202 mmol/g), respectively (Fig. 2I). The concentra-
tion in the small intestinal mucosa was at 31 mmol/g (21e47 mmol/
g) 2 h after treatment and decreased to 2 mmol/g (0e5 mmol/g) after
5 and 8 h post-treatment. Oxantel pamoate's plasma levels were
below the LLOQ (0.7 mM) at all times (Fig. 2J).
Fig. 2. In vivo distribution of albendazole, mebendazole and oxantel pamoate in host and T. muris. Columns of host samples are averages of n ¼ 3 mice and columns of parasite
samples are averages of n ¼ 9 measurements (3 samples per mouse). Error bars indicate the standard deviation. ABZ: albendazole (black columns); albendazole sulfoxide (gray
columns); albendazole sulfone (white columns); MBZ: mebendazole (striped columns); OxP: oxantel pamoate (dotted columns); po: per oral application; ip: intraperitoneal; GI:
gastrointestinal.
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kg) into the peritoneal cavity oxantel pamoate concentrations in
the stomach were 5 mmol/g (1e8 mmol/g), in the small intestine
7 mmol/g (4e9 mmol/g) and in the large intestine 7 mmol/g
(7e9 mmol/g). In the mucosal tissue of the small intestine, 2 mmol/g
(1e3 mmol/g) was found and 17 mmol/g (3e45 mmol/g) were
detected in the mucosal tissue of the large intestine (Fig. 2K). The
plasma levels were below the LLOQ, nevertheless, a concentration
of 0.21 mM (0.20e0.21 mM) was determined (Fig. 2J).
Oral application of oxantel pamoate resulted in accumulation in
T. muris only after 5 h (34 nmol/10 worms) and 8 h (22 nmol/10
worms) post-treatment (Fig. 2L). After the intraperitoneal appli-
cation of oxantel pamoate no compound could be quantiﬁed. No
correlation between the concentration in T. muris and in the large
intestinal content was apparent.
3.4. In vitro and in vivo drug activities
3.4.1. Albendazole, albendazole sulfoxide, and albendazole sulfone
activities against H. polygyrus
Albendazole and its two main metabolites showed poor in vitro
activity at 200 mM: the drug effect (reduction of parasite viability)
was 50% for albendazole, 60% for albendazole sulfoxide, and 40% for
albendazole sulfone (Table 2). All parasites were alive at the end of
the assay (72 h post-incubation).
3.4.2. Efﬁcacy of albendazole sulfoxide and albendazole plus ABT
against H. polygyrus
Albendazole sulfoxide (100 mg/kg) revealed a WBR of 79% in
H. polygyrus-infected mice, whereas albendazole (100 mg/kg) with
an ABT-pretreatment (50 mg/kg) reduced the worm burden by 84%
(Table 2).
4. Discussion
Albendazole and mebendazole are widely used drugs for the
treatment of soil-transmitted helminth infections (World Health
Organisation, 2006). Based on ﬁndings with other drug-parasite
systems these drugs are likely to enter the parasites from the in-
testinal lumen via the cuticle (Alvarez et al., 2007; Hansen et al.,
2014). However this has yet to be demonstrated for H. polygyrus
and T. muris.
This study was conducted to assess the distribution of alben-
dazole, its metabolites albendazole sulfoxide (an active anthel-
mintic) and albendazole sulfone (the main and inactive metabolite
of albendazole sulfoxide) in different compartments of the host and
the worm itself to shed light on the compartment responsible forTable 2
In vitro and in vivo activities albendazole (with or without ABT pre-treatment), alben
mebendazole and oxantel pamoate against T. muris.
Drug Drug effect [%] after drug
incubation [mM] of adult
H. polygyrus for 72 h
Worm burden reduction [%] after





Albendazole 50% [200 mM] 100% [100 mg/kg]a <5
Albendazole
sulfoxide
60% [200 mM] 79% [100 mg/kg] no
Albendazole
sulfone
40% [200 mM] not done no
Albendazole þ ABT not done 84% [100 mg/kg] no
Mebendazole 0% [100 mM]a 59% [100 mg/kg]a <5
Oxantel pamoate not done not done 4
EC50: Concentration of 50% drug efﬁcacy.
a Unpublished data.
b Keiser et al., 2012.
c Keiser et al., 2013.drug accumulation and drug activity against H. polygyrus, and
albendazole and mebendazole against T. muris. We also included
oxantel pamoate in our studies, because it is a promising drug for
the treatment of trichuriasis (Speich et al., 2015). We used two
helminth-mouse models: the H. polygyrus-NMRI model, which is a
model for hookworm infections (Tritten et al., 2012) and the
T. muris-C57BL/10 model, which is an established model for tri-
churiasis (Keiser et al., 2013). Several procedures used in this study
were validated for their quantitative (e.g. washing steps or
analytical methods) and qualitative (i.e. veriﬁcation of metabolite
identities using mass spectrometry) reliability.
4.1. Distribution and metabolism of albendazole
Albendazole revealed a very dynamic distribution and high rate
of metabolism. In mice, we observed both the parent as well as the
metabolites throughout the entire gastrointestinal tract after oral
treatment of albendazole as well as albendazole sulfoxide during all
time points of sampling. The distribution and pathways of alben-
dazole and its metabolites as observed in our study are depicted in
Fig. 3. The oxidative metabolism of albendazole to albendazole
sulfoxide and to albendazole sulfone occurred already in the
stomach of the mice. Reduction of albendazole sulfoxide to alben-
dazole took also place, however to a smaller extent. These bio-
transformations had already been demonstrated using artiﬁcial
cow rumens. In cows, bacterial metabolism is probably responsible
for these reactions, since inactivation with heat showed no trans-
formation of albendazole or albendazole sulfoxide (Capece et al.,
2001). Our study, in contrast, showed no transformations in iso-
lated stomach content, or in any of the gastrointestinal contents.
This suggests that the entire, or a major part of themetabolism, was
caused by host gastrointestinal epithelial cells. However, in depth
studies would be required, including studies on gastrointestinal
microbiota, which are able to metabolize xenobiotics (for instance
via oxidation and reduction) (Mikov, 1994), to fully understand the
role of the gut ﬂora in albendazole metabolism.
After oral application of albendazole sulfoxide the highest
amounts of albendazole were found in the large intestine. Smaller
amounts of albendazole were also found in the small intestinal
content, but this might have originated from the passage through
the stomach, where albendazole was present in slightly higher
quantity. The high amounts of albendazole in the large intestine is
unlikely to be due to efﬂux across the intestinal wall, since in the
blood stream albendazole is quickly oxidized to its sulfoxide
metabolite (Dayan, 2003). Therefore, it is probable that albendazole
is either transformed from albendazole sulfoxide by the gut ﬂora, or
by the epithelial cells and released back into the gastrointestinaldazole sulfoxide, and albendazole sulfone against H. polygyrus, and albendazole,
ug effect [%] after drug incubation of adult
muris at >600 mM or EC50 [mM] after
cubation at serial dilution for 72 h
Worm burden reduction [%] after oral
drug application of drugs [mg/kg] to
T. muris-infected mice
0%b 42% [300 mg/kg]c
t done not done
t done not done
t done not done
0%b 68% [150 mg/kg]c
mMc 93% [10 mg/kg]c
Fig. 3. Scheme of albendazole (ABZ), albendazole sulfoxide (ABZSO), and albendazole sulfone (ABZSO2) distribution in hosts and H. polygyrus and T. muris. H. polygyrus is depicted
wave-shaped and T. muris banana-shaped. Thin continuous arrows indicate known and highly probable pathways of drugs; thick continuous arrows indicate pathways of drugs
observed in this study, measured at concentrations above LLOQ; dashed arrows indicate assumed pathways of drugs; dashed crossed arrows indicate probable pathways, but not
detected in vitro.
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We also applied the treatments into the peritoneal cavity, a
method used to circumvent the gastrointestinal tract to directly
enter the blood stream - an alternative to intravenous injection for
small animals (Turner et al., 2011). The qualitative distribution was
similar to the oral treatments. The presence of albendazole sulf-
oxide in the gastrointestinal tract after intraperitoneal application
of albendazole was not surprising since efﬂux of albendazole sulf-
oxide from the blood stream across the small intestinal wall into
the gastrointestinal tract has been described for rats and sheep
(Merino et al., 2003). After intraperitoneal injection of albendazole
sulfoxide, albendazole was only found in the large intestinal con-
tent and the mucosal tissue; hence, albendazole seems to be
exclusively formed in the large intestine.
Quantitatively speaking, we experienced immense differences
in drug exposure between the two nematode models. While the
drug exposures in the two models were in the same magnitude
after oral treatment of albendazole, NMRI mice showed a 62-fold
increase of albendazole sulfoxide exposure, and albendazole sul-
fone a 500-fold increased exposure after intraperitoneal treat-
ments, whereas C57BL/10 mice showed no such difference.
Whether these different exposures between mouse strains are due
to differences in absorption into the circulation, efﬂux into the
gastrointestinal tract or metabolic speed has yet to be evaluated.
Strongly elevated concentrations of albendazole and its me-
tabolites were also observed in the mucosal tissue of NMRI mice
intraperitoneally treated with albendazole. While the highest
concentrations after oral application was at 30 mmol/g drug in
mucosal tissue, after the intraperitoneal application the concen-
trations were above 400 mmol/g. However, sampling mucosal tissue
was the most difﬁcult of all compartment samples. Therefore, we
evaluated the results for mucosal tissues with reservation. To
further investigate the relationship between host mucosal tissueand the parasites and their drug exchange, we suggest experiments
in a larger animal, such as the T. suis-pig model, offering larger
sample quantities. Furthermore, an omnivorous animal might
represent a more accurate model for human-parasite interactions
than herbivorous mice.
Also H. polygyrus recovered from intraperitoneally treated mice
revealed higher albendazole sulfone concentrations (Fig. 1J)
compared to the oral treatments. The accumulation of albendazole
sulfone could be a result of absorption from the host (Fig. 1C, F, and
I) or a result of H. polygyrus absorbing albendazole or albendazole
sulfoxide and metabolizing it to albendazole sulfoxide (Table 1).
Besides the host's metabolism, our in vitro experiments also
showed drug biotransformation by the two helminths. Both were
able to transform albendazole into the sulfoxide and the sulfone
metabolites; H. polygyrus to a higher extent than T. muris. T. muris
released albendazole sulfoxide only in very low quantities into the
medium in vitro (Table 1), which suggests the albendazole sulfoxide
found in the host's large intestine to origin from the host itself. Only
H. polygyruswas able to reduce albendazole sulfone to albendazole
sulfoxide. However, we did not observe a high rate of biotransfor-
mation to reach depletion of the respective parent compounds
(data not shown). The ability of nematodes to metabolize absorbed
drug and release the products into the environment further com-
plicates the interpretation of in vivo drug uptake into the parasites.
Moreover, the higher in vitro drug elimination by H. polygyrus
(albendazole-susceptible nematode in vivo) as opposed to the
lower elimination by T. muris (albendazole-unsusceptible nema-
tode in vivo) imply that lack of drug activity is not a result of
increased drug elimination in the helminth models used.
Interestingly, albendazole sulfone was absorbed more into
T. muris than the more lipophilic albendazole and albendazole
sulfoxide. This stands in contrast with the common hypothesis of a
correlation between compound lipophilicity and drug absorption
Fig. 4. Scheme of mebendazole (MBZ) distribution in host and T. muris. T. muris is depicted banana-shaped. Thin continuous arrows indicate known and highly probable pathways
of mebendazole; thick continuous arrows indicate pathways observed in this study, measured at concentrations above LLOQ; dashed arrows indicate assumed pathways.
Fig. 5. Scheme of oxantel pamoate salt (Ox$P) distribution in host and T. muris. T. muris is depicted banana-shaped. Thin continuous arrows indicate known and highly probable
pathways of oxantel pamoate; thick continuous arrows indicate pathways observed in this study, measured at concentrations above LLOQ; dashed arrows indicate assumed
pathways.
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explanation for this ﬁnding.
ABT, an irreversible and CYP-unspeciﬁc inhibitor, was incorpo-
rated into the experimental design to assess the importance of CYP
metabolism in the hookworm model. In the host, treatment of ABT
prior to albendazole led to higher amounts of unchanged alben-
dazole in the stomach and in the large intestine. Furthermore,
elevated concentrations of albendazole sulfoxide were present the
in plasma, especially in the gastrointestinal content. The elevated
drug level after ABT pre-treatment are likely to be caused by CYP
inhibition. However, since metabolism took place despite ABT pre-treatment, involvement of non-CYP enzymes in albendazole
metabolism in the gut or incomplete CYP inactivation by ABT are
probable. In contrast to ABT's effect on the distribution in the host,
the worms recovered from ABT pre-treated mice prior to alben-
dazole treatment showed no difference in the accumulation of
albendazole and its metabolites compared to worms recovered
from albendazole only treated mice. This ﬁnding is in line with our
in vitro studies, where ABT had no effect on the uptake and elimi-
nation of albendazole by H. polygyrus. However, CYPs have been
described to be involved in benzimidazole metabolism in various
helminths (Matouskova et al., 2016), including H. polygyrus
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dazole metabolism in H. polygyrus, or whether ABT did not sufﬁ-
ciently inactivate the suitable CYP (Emoto et al., 2005) is not clear at
this point. ABT's inhibitory effect in H. polygyrus drug metabolism
could be further assessed using other drugs known for CYP
metabolism.
The in vitro studies showed that the extent of drug uptake and
elimination by the helminths is not always a function of the con-
centration of drug exposure. It is therefore crucial to test drug
uptake and elimination at different concentrations and preferably
at pharmacologically relevant concentrations to draw conclusions
about a drug's accumulation in the worm.
To sum up, albendazole and its metabolites were highly
distributed in the host after oral and intraperitoneal application.
Additionally, the drug concentrations in worms recovered from
treated mice did not correlate with any compartment of the host
nor anthelmintic activity. Therefore, we could not determine the
compartment responsible for albendazole and albendazole sulf-
oxide uptake and efﬁcacy.
4.2. Distribution of mebendazole
After oral application of mebendazole to T. muris-infected mice,
the progression of mebendazole down the enteric route was visible
with a continuous exposure of all compartments tested during 8 h.
The distribution and pathways of mebendazole are depicted in
Fig. 4. Comparable exposures were observed after intraperitoneal
application compared to oral application of mebendazole in all
compartments, also in the stomach. Efﬂux from the blood stream
into the gastrointestinal tract might be the reason for mebendazole
exposure in the gastrointestinal tract. However, to our knowledge,
this mechanism has not been described. Mebendazole concentra-
tions found in T. muris recovered from treated mice did not corre-
late with any compartment tested. Furthermore, in vitro exposure
to serial drug dilution showed similar amounts of accumulation for
all concentrations. Obviously, in case drug uptake into helminths
reaches saturation, comparison between drug concentrations in
different compartments of the host with the concentrations in the
helminths cannot be used to identify the pathway of drug entry.
Nevertheless, this study demonstrated that the higher efﬁcacy
of mebendazole against T. muris compared to albendazole (Table 2)
is not a result of better drug absorption because post-treatment
both drugs were measured in similar concentrations. In addition,
our data hint that levels of mebendazole in the large intestine and
cuticular penetration dominate the pathway of drug entry, since
concentrations measured in T. muris recovered from treated mice
follow rather the pattern of mebendazole found in the large in-
testine than in the plasma. However, if this pathway is responsible
for the anthelmintic activity is not known.
4.3. Distribution of oxantel pamoate
Also for oxantel pamoate a clear progression down the gastro-
intestinal tract was visible, with a persistent drug exposure during
8 h. The distribution and pathways of oxantel pamoate is depicted
in Fig. 5. Three characteristics were noted: First, the stomach con-
tained high amounts of oxantel pamoate at all time points after oral
application, especially 2 h after treatment. The generally high
values of oxantel pamoate in the gastrointestinal tract conﬁrm that
the drug is only little or not at all metabolized. Second, no plasma or
mucosa sample contained oxantel pamoate in quantiﬁable
amounts. Third, only very low concentrations of oxantel pamoate
could be found in the host's intestinal tract after peritoneal appli-
cation of the drug and the concentration in the parasites was
negligible. These ﬁndings conﬁrm that oxantel pamoate is not (oronly very little) absorbed or generally distributed across compart-
ments. T. muris recovered from mice treated with oxantel pamoate
contained the drug after 5 and 8 h post-treatment (same time
points at which oxantel pamoate was present in the large intes-
tine), but contained none 2 h after oral as well as intraperitoneal
treatment (sampling time points at which no oxantel pamoate was
present in the large intestine). The results indicate that drug can
enter T. muris only via gastrointestinal contents and activity is
driven by drug levels in the large intestine.
4.4. Albendazole and mebendazole drug activities
In addition to the drug distribution and metabolism studies, we
also assessed the in vitro and in vivo activity of albendazole sulf-
oxide against H. polygyrus. In vitro, H. polygyrus adults were not
affected by albendazole sulfoxide; however, also albendazole and
mebendazole are known for low activity against adult H. polygyrus
in vitro (Table 2). In vivo, despite shorter exposure timewe observed
high activity of albendazole sulfoxide at a single oral dose of
100 mg/kg, with a WBR of 79%. Moreover, we tested the efﬁcacy of
albendazole with a pre-treatment with ABT to assess the inﬂuence
of CYP inhibition: the worm burden was reduced by 84%, whereas
for comparison, albendazole (100 mg/kg) and mebendazole
(150 mg/kg) alone resulted in a worm reduction of 100% and 68%,
respectively (Table 2). The reason for the differences between the
in vitro and in vivo activities of albendazole is not known at the
moment and are difﬁcult to explain with the data generated in this
study.
5. Conclusion
Our distribution studies showed no link between drug accu-
mulation in the target parasite and drug efﬁcacy. Clearly, drug ef-
ﬁcacy is not a matter of howmuch drug accumulates in the worms,
but how much drug interacts with the target. Currently, rodent
models are widely used in preclinical pharmacokinetic studies due
to their relatively easy handling and low costs (Zhang et al., 2012);
however, comparable studies using animal models that are closer
to human physiology, i.e. pigs, might be beneﬁcial. More experi-
ments employing “inert” compounds (such as oxantel pamoate,
which do almost not leave the compartment of application and
seems not to bemetabolized)might be beneﬁcial for further studies
to exclude bias by ubiquitous presence and drug elimination.
Furthermore, autoradiographic techniques (Solon, 2015) or imaging
mass spectrometry (Karlsson and Hanrieder, 2016) might be
employed to trace drug entry into theworm and distributionwithin
the worm. Comparison of oral and intravenous application of such
compounds might be valuable to elucidate the distribution, de-
livery to the target parasite and the resulting efﬁcacy. However,
whether a general pathway can be determined may be disputed.
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